openPR Logo
Press release

H1N1 Vaccination Market - Strategic Assessment and Forecast Till 2023

04-14-2017 02:46 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

H1N1 Vaccination Market - Strategic Assessment and Forecast

H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred as swine flu. The H1N1 virus mainly affects the respiratory system including nose, lungs and throat of the infected person. In addition to human, H1N1 virus affects various species such as birds, swine, horses etc. The H1N1 influenza virus caused a worldwide pandemic in the recent years. H1N1 virus can be classified on the basis of antigenicity of its surface glycoproteins neuraminidase and hemagglutinin. Hemagglutinin helps the virus to bind to host cell receptors. This simplifies viral entry into the host cell. Neuraminidase protein enzymatically splits terminal sialic acid residues from mucins, thereby letting the virus to reach underlying cells in the respiratory tract. The global H1N1 vaccination are administered to for active immunization against the H1N1 influenza virus. The global H1N1 vaccination market is anticipated to boost in the focus period due to the rising cases of swine flu. Additionally, the rising geriatric population increases the risk of respiratory tract diseases, and immune deficient diseases, thus increasing the risk factor for acquiring H1N1 influenza. Moreover, increased research in the field of vaccine technologies and significant government support are driving this market. However, lack of awareness and absence of experienced medical professionals are restraining the growth of H1N1 vaccines market. Furthermore, high capital requirement and stringent regulations are also hindering the growth of the global H1N1 vaccination market.

Browse Complete Report Details of this Market at: http://www.transparencymarketresearch.com/h1n1-vaccination-market.html

The global H1N1 vaccination market has been augmented based on brands. The drugs brands include Agripal (Panacea Biotec Ltd), Fiuarix (GSK Pharmaceuticals Ltd), Influgen (Lupin Laboratories Ltd.), Influvac (Solvay Pharma India Pvt Ltd), Nasovac (Serum Institute of India Ltd.), Vaxigrip (Sonofi Pasteur) and others.

North America and Europe lead the global H1N1 vaccination market in terms of revenue. This is majorly due to the developed research infrastructure in these regions. The U.S. holds the largest market for H1N1 vaccination, followed by Canada, in North America. In Europe, Germany and France dominate H1N1 vaccination market. However, the Asian H1N1 vaccines market is expected to exhibit a high growth rate during the forecast period due rising cases in the region, particularly in India. Moreover, increasing awareness among the masses about the diseases coupled with growing government initiatives and programs to raise awareness among people about various infectious diseases in Asia. This has resulted in the significant rise in demand for H1N1 vaccines for the prevention of swine flu. Moreover, several companies are constructing their manufacturing and research facilities in developing regions given the low wages to be paid, availability of a large talent pool, and less stringent environment and health and safety regulations. Growing medical infrastructure and economies in developing countries such as India and China, the discovery of new vaccines with greater efficiency, and advancements in the field of biomedical science are expected to offer good opportunities to the players in the H1N1 vaccines market. Frequent strategic collaborations and mergers between manufacturing companies and government associations as well as product launches are the current trends in the global H1N1 vaccines market.

Obtain the Sample PDF Research Report for this Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6913

Some of the major players operating in the global H1N1 vaccination market are AstraZeneca plc, Medimmune, GlaxoSmithKline, Novartis, and Sanofi Pasteur. Baxter, Sinovac, Commonwealth Serum Laboratories, Zydus Cadila and Others.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release H1N1 Vaccination Market - Strategic Assessment and Forecast Till 2023 here

News-ID: 502813 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for H1N1

H1N1 Vaccines Market Opportunity Analysis, 2018 – 2026
H1N1 influenza virus causes viral disease, commonly known as swine flu, which mostly affects the respiratory system. Swine flu is characterized by infection from H1N1 strain. Symptoms of H1N1 flu are fever, cough, sore throat, runny or stuffy nose, watery and red eyes, body aches, headache, fatigue, and diarrhea. H1N1 spreads through contact with contaminated air or geographical locations infected with virus. H1N1 infection may worsen other chronic respiratory conditions
H1N1 Vaccines Market Expansion to be Persistent by 2021
A vaccine is a biological preparation consisting of an agent that closely resembles a disease-causing microorganism and is made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. Vaccines can be categorized into many types such as inactivated vaccines, attenuated vaccines, toxoid, and conjugate. Cholera, influenza, hepatitis A, polio, and rabies vaccines are inactivated vaccines. The global vaccines market is categorized on the
H1N1 Vaccination Market - Global Industry Analysis 2023
H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred as swine flu. The H1N1 virus mainly affects the respiratory system including nose, lungs and throat of the infected person. In addition to human, H1N1 virus affects various species such as birds, swine, horses etc. The H1N1 influenza virus caused a worldwide pandemic in the recent
H1N1 Vaccination Market Opportunities and Forecast by 2023
H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred as swine flu. The H1N1 virus mainly affects the respiratory system including nose, lungs and throat of the infected person. In addition to human, H1N1 virus affects various species such as birds, swine, horses etc. The H1N1 influenza virus caused a worldwide pandemic in the recent
H1N1 Vaccines Market Rugged Expansion Foreseen by 2021
The H1N1 Vaccines Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. A vaccine is a biological preparation consisting of an agent that closely resembles a disease-causing microorganism and is made from weakened or killed forms of the microbe, its toxins or one
Europe H1N1 Vaccines Market 2017
Latest market study on " Europe H1N1 Vaccines Market Report: 2017 " available with Single User Europe USD 3900 at OrbisResearch.com The H1N1 Vaccines Market report covers the present scenario and the growth prospects of the Europe H1N1 Vaccines market for 2017-2022 The report covers the market landscape and its growth prospects over the coming years. To calculate the market size , market share, market growth, market analysis , market